| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V4282 | AZ7550 Mesylate | 2319837-99-3 | AZ7550 Mesylate (AZ-7550), the mesylate salt ofAZ 7550, is an active metabolite ofAZD-9291 (Osimertinib) by removing one of the methyl groups from the ethyl diamine side chain. |
|
V69398 | Becotatug (JMT-101) | 2648260-93-7 | Becotatug (JMT-101) is an IgG1 antibody targeting EGFR and can also be coupled with Afatinib and Osimertinib to form an ADC. |
|
V69401 | DBPR112 | 1226549-49-0 | DBPR112 is an orally bioactive fluoropyrimidine-based EGFR inhibitor (antagonist) with IC50s of 15 nM and 48 nM for EGFRWT and EGFRL858R/T790M, respectively. |
|
V69381 | DHFR-IN-4 | 2820126-49-4 | DHFR-IN-4 is a potent dihydrofolate reductase (DHFR) inhibitor (antagonist) with IC50 of 123 nM. |
|
V77049 | EGFR T790M/L858R-IN-2 | EGFRT790M/L858R-IN-2 is a potent and specific EGFRT790M/L858R inhibitor (antagonist) with IC50s of 3.5 and 1290 nM for EGFRT790M/L858R and EGFR WT respectively. | |
|
V69414 | EGFR-IN-15 | 2573869-16-4 | EGFR-IN-15 (compound I-005) is an EGFR inhibitor (antagonist) with IC50 of 4 nM. |
|
V69427 | EGFR-IN-16 | 133550-22-8 | EGFR-IN-16 (compound 3) is a potent EGFR inhibitor (antagonist) with pIC50s of 4.85 and 4.74 for EGFR and HER-2, respectively. |
|
V79490 | EGFR-IN-83 | EGFR-IN-83 (Compound 9) is an EGFR inhibitor (IC50= 2.53 nM). | |
|
V79925 | EGFR-IN-86 | EGFR-IN-86 (compound 4i) is an EGFR inhibitor (IC50= 1.5 nM) with high activity against glioblastoma. | |
|
V69432 | EGFR/BRAF-IN-1 | 2906174-89-6 | EGFR/BRAF-IN-1 (compound 21) is a 2,3-dihydropyrazino[1,2-a]indole-1,4-dione analogue, a potent EGFR/BRAF inhibitor, with IC50 of BRAFV600E is 45 nM. |
|
V69409 | EGFR/CSC-IN-1 | 2820447-02-5 | EGFR/CSC-IN-1 is a potential dual (bifunctional) inhibitor of EGFR (IC50 10.52 nM) and cancer stem cells (CSC) for triple-negative breast cancer research. |
|
V69383 | EGFR/HER2-IN-7 | 2820126-28-9 | EGFR/HER2-IN-7 is a potent anticancer agent with high selectivity for cancer cells and specifically acts on breast cancer cells MCF-7. |
|
V69420 | EMI1 | 35773-42-3 | EMI1 is a potent inhibitor of the EGFR triple mutants EGFR ex19del/T790M/C797S and EGFR L858R/T790M/C797S. |
|
V69413 | EMI48 | 34564-13-1 | EMI48 is an analogue of EMI1 and has greater potency against mutant EGFR than EMI1. |
|
V69410 | EMI56 | 2414374-41-5 | EMI56 is an analogue of EMI1 and has greater potency against mutant EGFR than EMI1. |
|
V69339 | JCN037 (JGK037) | 2305154-31-6 | JCN037 (JGK037) is a potent, covalent, BBB (blood-brain barrier) permeable (penetrable) EGFR inhibitor (antagonist) with IC50s of 2.49 nM, 3.95 nM and 4.48 nM for EGFR, p-wtEGFR and pEGFRvIII respectively. |
|
V81005 | Oligopeptide-41 | Oligopeptide-41 is a biologically active peptide with hair growth-promoting effects that has been reported for use as an ingredient of cosmetics. | |
|
V81015 | Os30 | 2998928-68-8 | Os30 is a potent fourth-generation EGFR inhibitor and a potent EGFRC797S-TK inhibitor (antagonist) with IC50s of 18 nM and 113 nM for EGFRDel19/T790M/C797S TK and EGFRL858R/T790M/C797S TK, respectively. |
|
V69382 | PROTAC EGFR degrader 8 | 2925923-46-0 | PROTAC EGFR degrader 8 (T-184) is a PROTAC EGFR degrader. |
|
V69434 | Simotinib hydrochloride | 1538617-88-7 | Simotinib HCl is a selective, specific, orally bioavailable EGFR tyrosine kinase inhibitor (TKI) (antagonist) with IC50 of 19.9 nM. |